Evoke Wealth’s Aprea Therapeutics APRE Stock Holding History

Evoke Wealth’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22	Closed	-$17K	–	1016
2020 Q2	$17K	Buy	+22	New	+$14.4K	﹤0.01%	492

Other funds holding APRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Evoke Wealth's APRE Position: Q3 2020 in Review

Evoke Wealth sold out of Aprea Therapeutics (APRE) in Q3 2020, closing a stake of 22 shares — an estimated $17K sold.

Evoke Wealth first reported a position in APRE in Q2 2020 and held it in 1 quarter. The position peaked at $17K in Q2 2020. 64 funds tracked by Wall St. Rank hold APRE as of Q3 2020.

Evoke Wealth reported no remaining Aprea Therapeutics position as of Q3 2020 after selling out during the quarter.
Evoke Wealth sold 22 Aprea Therapeutics shares in Q3 2020, an estimated $17K.
Evoke Wealth first reported a position in Aprea Therapeutics in Q2 2020 and held it in 1 quarter.
Evoke Wealth's Aprea Therapeutics position peaked at $17K in Q2 2020.
64 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2020.

Based on Evoke Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.